14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $1.95 $2.61 Monday, 22nd Apr 2024 CHRS stock ended at $2.18. This is 5.31% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 7.35% from a day low at $2.04 to a day high of $2.19.
90 days $1.93 $2.87
52 weeks $1.44 $8.33

Historical Coherus BioSciences prices

Date Open High Low Close Volume
Apr 22, 2024 $2.07 $2.19 $2.04 $2.18 1 492 056
Apr 19, 2024 $2.01 $2.09 $1.95 $2.07 2 871 321
Apr 18, 2024 $2.15 $2.19 $1.99 $2.00 1 890 060
Apr 17, 2024 $2.17 $2.22 $2.12 $2.15 1 255 281
Apr 16, 2024 $2.21 $2.21 $2.12 $2.15 1 368 480
Apr 15, 2024 $2.21 $2.24 $2.14 $2.20 2 107 978
Apr 12, 2024 $2.38 $2.43 $2.20 $2.23 2 024 263
Apr 11, 2024 $2.46 $2.52 $2.33 $2.41 1 739 632
Apr 10, 2024 $2.36 $2.46 $2.32 $2.45 1 620 974
Apr 09, 2024 $2.53 $2.61 $2.46 $2.47 1 433 170
Apr 08, 2024 $2.45 $2.55 $2.44 $2.51 2 007 565
Apr 05, 2024 $2.33 $2.48 $2.25 $2.43 1 465 787
Apr 04, 2024 $2.43 $2.45 $2.30 $2.33 1 478 195
Apr 03, 2024 $2.34 $2.49 $2.30 $2.38 2 682 561
Apr 02, 2024 $2.34 $2.37 $2.27 $2.36 1 399 941
Apr 01, 2024 $2.40 $2.42 $2.30 $2.40 1 770 617
Mar 28, 2024 $2.42 $2.51 $2.36 $2.39 2 092 615
Mar 27, 2024 $2.32 $2.44 $2.28 $2.42 2 562 634
Mar 26, 2024 $2.32 $2.39 $2.29 $2.30 3 125 184
Mar 25, 2024 $2.33 $2.40 $2.26 $2.28 1 913 147
Mar 22, 2024 $2.48 $2.49 $2.32 $2.33 2 038 549
Mar 21, 2024 $2.52 $2.64 $2.47 $2.51 3 269 299
Mar 20, 2024 $2.40 $2.55 $2.35 $2.48 3 851 690
Mar 19, 2024 $2.21 $2.48 $2.18 $2.45 3 400 685
Mar 18, 2024 $2.22 $2.26 $2.14 $2.22 2 540 411
Click to get the best stock tips daily for free!

About Coherus BioSciences

Coherus BioSciences Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma ... CHRS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT